{"name":"Harmony Biosciences","slug":"horizon-medicine","ticker":"HRMY","exchange":"NASDAQ","domain":"harmonybiosciences.com","description":"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fr","hq":"Plymouth Meeting, PA, USA","founded":0,"employees":"293","ceo":"John C. Jacobs","sector":"Neuroscience / Rare Disease","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":28.73,"stockChange":1.11,"stockChangePercent":4.02,"marketCap":"$1.7B","metrics":{"revenue":868453000,"revenueGrowth":21.1,"grossMargin":77.2,"rdSpend":189594000,"netIncome":158687000,"cash":775340032,"dividendYield":0,"peRatio":10.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"WAKIX patent cliff ($143.6M at risk)","drug":"WAKIX","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Open-label pitolisant","genericName":"Open-label pitolisant","slug":"open-label-pitolisant","indication":"Narcolepsy type 1 and type 2","status":"phase_3"},{"name":"Pitolisant oral tablets","genericName":"Pitolisant oral tablets","slug":"pitolisant-oral-tablets","indication":"Other","status":"phase_2"},{"name":"Double-blind pitolisant","genericName":"Double-blind pitolisant","slug":"double-blind-pitolisant","indication":"Narcolepsy type 1 and type 2","status":"phase_3"},{"name":"HBS-201","genericName":"HBS-201","slug":"hbs-201","indication":"Other","status":"phase_1"},{"name":"Pitolisant tablet","genericName":"Pitolisant tablet","slug":"pitolisant-tablet","indication":"Narcolepsy type 1 and type 2","status":"phase_3"},{"name":"ZYN002","genericName":"ZYN002","slug":"zyn002","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Open-label pitolisant","genericName":"Open-label pitolisant","slug":"open-label-pitolisant","phase":"phase_3","mechanism":"Pitolisant is a selective histamine H3 receptor antagonist that increases wakefulness by blocking inhibitory histamine signaling in the brain.","indications":["Narcolepsy type 1 and type 2","Idiopathic hypersomnia"],"catalyst":""},{"name":"Pitolisant oral tablets","genericName":"Pitolisant oral tablets","slug":"pitolisant-oral-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Double-blind pitolisant","genericName":"Double-blind pitolisant","slug":"double-blind-pitolisant","phase":"phase_3","mechanism":"Pitolisant is a selective histamine H3 receptor antagonist that increases wakefulness by blocking inhibitory histamine signaling in the brain.","indications":["Narcolepsy type 1 and type 2","Idiopathic hypersomnia"],"catalyst":""},{"name":"HBS-201","genericName":"HBS-201","slug":"hbs-201","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pitolisant tablet","genericName":"Pitolisant tablet","slug":"pitolisant-tablet","phase":"phase_3","mechanism":"Pitolisant is a selective histamine H3 receptor antagonist that increases histamine release in the brain to promote wakefulness.","indications":["Narcolepsy type 1 and type 2","Excessive daytime sleepiness associated with narcolepsy"],"catalyst":""},{"name":"ZYN002","genericName":"ZYN002","slug":"zyn002","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"The company reported net sales of $143.6 million for the full year 2023, representing a 34% increase from 2022.","drugName":"","sentiment":"positive"},{"date":"2023-12-14","type":"deal","headline":"Harmony Biosciences Announces Collaboration with the National Narcolepsy Foundation","summary":"The company partnered with the National Narcolepsy Foundation to raise awareness and support for narcolepsy patients.","drugName":"","sentiment":"neutral"},{"date":"2023-09-15","type":"regulatory","headline":"Harmony Biosciences Submits New Drug Application for JZP-258","summary":"The company submitted an NDA for JZP-258, a potential treatment for cataplexy in patients with narcolepsy.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFAxWXJobXFZM0lyNjdOTkpRNzBtS09BRklkMFgtakFRb1duUGx6YS1hSmdpa1JaYXVXYnJVM3NiYnZBbEJFY2hhWmo4OW9GQ1VsWXc?oc=5","date":"2026-04-05","type":"pipeline","source":"Yahoo Finance UK","summary":"Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history - Yahoo Finance UK","headline":"Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"pipeline","source":"simplywall.st","summary":"How Investors May Respond To Harmony Biosciences (HRMY) Strengthening Its C-Suite And Board For Execution - simplywall.st","headline":"How Investors May Respond To Harmony Biosciences (HRMY) Strengthening Its C-Suite And Board For Execution","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"simplywall.st","summary":"A Look At Harmony Biosciences Holdings (HRMY) Valuation After Recent Share Price Weakness - simplywall.st","headline":"A Look At Harmony Biosciences Holdings (HRMY) Valuation After Recent Share Price Weakness","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1FeWFXQUZqUERDelpUQXd6MjQxR2RaTjJWN1NkMFliQjNuY3JJUWkyZ2ZpSGFQeUR5ZTVYZ01VZWJmMWRiVV9YVWd5NXZ2SjZyY19OT0h6RzhOUWs1VkJkU1VyamZkdw?oc=5","date":"2026-03-14","type":"pipeline","source":"Stock Titan","summary":"HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"HRMY SEC Filings - Harmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-07","type":"earnings","source":"simplywall.st","summary":"Harmony Biosciences Holdings (HRMY) Valuation After Earnings, 2026 WAKIX Guidance And Upcoming Investor Conferences - simplywall.st","headline":"Harmony Biosciences Holdings (HRMY) Valuation After Earnings, 2026 WAKIX Guidance And Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPVTZEcnBjY3ZLMUR1UHRqVmQ4NlllRV92ejhWSHVES0FQVVZYcFlqczFzYThxZXBmbFk3SktqZWZGQllkblRZQnVPejQ2ZkZWS0QtbXJ2STZYeWppSHh2YjlqczdteW5NNEdvTElGMGQyVnJwVTc5VjN2SnZha29jN2FqZ3FSa0RZejVVaExSbGs0QXBibnVfdW5CZzFMWmhzWVNyeGpVTmRjNWlDSU1rTHJWUnp2Y3NNSmEtcno4ZG9jbEttMVc4c01nOGhBcHM3ZUJN?oc=5","date":"2026-02-26","type":"trial","source":"Finviz","summary":"Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments - Finviz","headline":"Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-24","type":"pipeline","source":"simplywall.st","summary":"Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential - simplywall.st","headline":"Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPbGxqVWM1ejVvU3pwV2hvLXVieXJHQVlTTWNDcW8ycGpNNThLMHFGd2xJQlpHYkptMmxrNW9sQ2Q4YVJPUG44SGx0NklDM0lpUDVkenVQQUFQYkp4VmpVeXlqY2hfZXNBOXFsbzI2OUZJX3pwNTdBOEd4RHFVc0J4bzRkbzNwZWdjSkJyOWJxRXZsQXhPaEVVWmlhN0VWTllxRVJLUFc5bkRnX1c0TEcyQ0hhNWZ5R1FhalY2M1NPbHFyNVpu?oc=5","date":"2026-02-23","type":"patent","source":"Investing.com","summary":"Deutsche Bank cuts Harmony Biosciences stock rating on patent risk - Investing.com","headline":"Deutsche Bank cuts Harmony Biosciences stock rating on patent risk","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQQXZxRXRoY2hsMWZVQllLQXE3cEg3d2F5TlF5alpJcEpoWW8xaE1Lc3JaLVRfa0FvcEtVTjJsOVpZQTQtWXVPZ3hmTDhoRm9MeS1BdEhkakp4Z2VhRk0yRm9CZll3aWEwSlVnOTFvVlpLa0hoVzJ4TVRSMTZBcllRYWpJbk9CMXAzdU45aGtDY3d6V1dkSXVpMXI3Tl85bWVxNW5nejBWbnVfdVhUbXhXVg?oc=5","date":"2025-09-25","type":"pipeline","source":"Seeking Alpha","summary":"Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY) - Seeking Alpha","headline":"Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOZGVJV0dHOEEwdWx6QnJnVFkwV2VZbXJqMV9yUnBwMEE2bVl2TjFkTmZCbVJ4UHJmOTlTZV9kUHNMaW0tc1M5TEpkODltMDNDU0J5V2RNNmZja0NoRnFiZW96OC1wQ3d0TDlKYnRraElLd2FHdVNjc3NzMXJMSnpKQ0FobHVQempZV3FQWlBPUVE0YjBDdXhCbTdrcFNFWDVZd0w0LTNRc0VqZER5RHhEUkloNFdsVW9OMDBMc1otQjAtemRDTDhKQnY0ZGZ4cTRLRkN3SnU2MVJPM1VpX2xDZXJXYUZPZw?oc=5","date":"2025-09-24","type":"trial","source":"Reuters","summary":"Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial - Reuters","headline":"Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPaFJ3d1lpSFRJYlFnNXBETHZ2M29ianVMV1hWRnlKUjY5a3pXc0tpVGxGR2hHUkY3bm94clNEZjY2TWFoRjIyZS0tTnEtNllMeEhKanRPSmVVS3pHWHl5akE1T1BQR09LLTdneWtxdHFnUWpzUXVIcDRVaW8yU3BEOTM5ZjVrRWI5TjFmSUNqM25mVzJ4blZmZ0ZfSDVlRnRJdG93dHc0OG9Gbm1iZ1BWSVBkS21oa1dIUXRqMDlMY3ZjV2k5aUtXR3FwVkJCWmY2bkJTaUlnZnFsTWN5VlE?oc=5","date":"2023-10-11","type":"pipeline","source":"PR Newswire","summary":"HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - PR Newswire","headline":"HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPRzRRMDQ3WFAtaFZIWmFRbU9ZTHo5SE1SZGl4TzJ2RkMyWU05MUNKSHNjQzFNeDhkeE1McXlDLUFfS1E2RE5LMU8zZXlZajNWN0s0ci1tY01LRUtYckpEUEJEN1hIYW1FaTQtcnRLZDBOVWFCTVVwNFpfTDB2TzZEbWtycGZqbEp4NGQyZ1dMTXg0Wkx5dVRrU0ZyTG5DaUp4TzJFWkozcWlMWHRJSlRQME8yYlc?oc=5","date":"2023-08-14","type":"deal","source":"PR Newswire","summary":"HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. - PR Newswire","headline":"HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.","sentiment":"neutral"}],"patents":[{"drugName":"WAKIX","drugSlug":"pitolisant","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":143600000}],"drugCount":6,"phaseCounts":{"phase_3":3,"phase_2":2,"phase_1":1},"enrichmentLevel":3,"visitCount":5,"keyCompetitors":["Valeant Pharmaceuticals","Ultragenyx Pharmaceutical","Pfizer Inc."],"therapeuticFocus":["Narcolepsy","Rare Neurological Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":868453000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":868453000,"period":"2025-12-31"},{"value":714734000,"period":"2024-12-31"},{"value":714734000,"period":"2024-12-31"},{"value":582022000,"period":"2023-12-31"},{"value":582022000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":189594000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":158687000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1271631000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":293,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":28.73,"previousClose":27.62,"fiftyTwoWeekHigh":40.87,"fiftyTwoWeekLow":25.52,"fiftyTwoWeekRange":"25.52 - 40.87","fiftyDayAverage":31.33,"twoHundredDayAverage":33.24,"beta":0.89,"enterpriseValue":991465728,"forwardPE":5,"priceToBook":1.91,"priceToSales":1.91,"enterpriseToRevenue":1.14,"enterpriseToEbitda":4.24,"pegRatio":0,"ebitda":233804000,"ebitdaMargin":26.9,"freeCashflow":211456496,"operatingCashflow":348199008,"totalDebt":169248000,"debtToEquity":19.4,"currentRatio":3.6,"returnOnAssets":11.5,"returnOnEquity":20.8,"analystRating":"","recommendationKey":"none","numberOfAnalysts":11,"targetMeanPrice":42,"targetHighPrice":62,"targetLowPrice":25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":12.1,"institutionHeldPercent":91.1,"sharesOutstanding":57867389,"floatShares":50902054,"sharesShort":7622382,"shortRatio":5.62,"shortPercentOfFloat":13.2,"epsTrailing":2.71,"epsForward":5.79,"revenuePerShare":15.11,"bookValue":15.07,"officers":[{"age":57,"name":"Mr. Jeffrey S. Aronin","title":"Founder & Non-Executive Chairman"},{"age":68,"name":"Dr. Jeffrey M. Dayno M.D.","title":"President, CEO & Director"},{"age":55,"name":"Mr. Peter  Anastasiou","title":"Chief Operating Officer"},{"age":54,"name":"Dr. Kumar  Budur M.D., M.S.","title":"Executive VP and Chief Medical & Scientific Officer"},{"age":50,"name":"Mr. Andrew  Serafin J.D., M.B.A.","title":"Executive VP & Chief Strategy Officer"},{"age":null,"name":"Brennan  Doyle","title":"VP & Head of Investor Relations"},{"age":null,"name":"Mr. Christian  Ulrich J.D.","title":"Executive VP, General Counsel & Corporate Secretary"},{"age":null,"name":"Ms. Tricia  Glover","title":"Chief Compliance Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.harmonybiosciences.com","phone":"484 539 9800"}}